FORFIVO XL Litigations
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7674479 | ALMATICA | Sustained-release bupropion and bupropion/mecamylamine tablets |
Jun, 2027
(3 years from now) | |
Forfivo Xl is owned by Almatica.
Forfivo Xl contains Bupropion Hydrochloride.
Forfivo Xl has a total of 1 drug patent out of which 0 drug patents have expired.
Forfivo Xl was authorised for market use on 10 November, 2011.
Forfivo Xl is available in tablet, extended release;oral dosage forms.
The generics of Forfivo Xl are possible to be released after 25 June, 2027.
Drugs and Companies using BUPROPION HYDROCHLORIDE ingredient
Market Authorisation Date: 10 November, 2011
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE;ORAL
How can I launch a generic of FORFIVO XL before it's drug patent expiration?
More Information on Dosage
FORFIVO XL family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic